Melanoma: From Melanocyte to Genetic Alterations and Clinical Options

被引:78
作者
Bertolotto, Corine [1 ,2 ]
机构
[1] INSERM, U1065 Equipe 1, C3M, F-06204 Nice, France
[2] Univ Nice Sophia Antipolis, UFR Med, F-06204 Nice, France
关键词
D O I
10.1155/2013/635203
中图分类号
Q [生物科学];
学科分类号
07 [理学]; 0710 [生物学]; 09 [农学];
摘要
Metastatic melanoma remained for decades without any effective treatment and was thus considered as a paradigm of cancer resistance. Recent progress with understanding of the molecular mechanisms underlying melanoma initiation and progression revealed that melanomas are genetically and phenotypically heterogeneous tumors. This recent progress has allowed for the development of treatment able to improve for the first time the overall disease-free survival of metastatic melanoma patients. However, clinical responses are still either too transient or limited to restricted patient subsets. The complete cure of metastatic melanoma therefore remains a challenge in the clinic. This review aims to present the recent knowledge and discoveries of the molecular mechanisms involved in melanoma pathogenesis and their exploitation into clinic that have recently facilitated bench to bedside advances.
引用
收藏
页数:22
相关论文
共 273 条
[1]
The melanocortin-1 receptor is a key regulator of human cutaneous pigmentation [J].
Abdel-Malek, Z ;
Scott, MC ;
Suzuki, I ;
Tada, A ;
Im, S ;
Lamoreux, L ;
Ito, S ;
Barsh, G ;
Hearing, VJ .
PIGMENT CELL RESEARCH, 2000, 13 :156-162
[2]
Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background [J].
Ackermann, J ;
Frutschi, M ;
Kaloulis, K ;
McKee, T ;
Trumpp, A ;
Beermann, F .
CANCER RESEARCH, 2005, 65 (10) :4005-4011
[3]
Agarwal Saurabh, 2012, Indian Dermatol Online J, V3, P144, DOI 10.4103/2229-5178.96722
[4]
Immunotherapy for Melanoma: Current Status and Perspectives [J].
Alexandrescu, Doru T. ;
Ichim, Thomas E. ;
Riordan, Neil H. ;
Marincola, Francesco M. ;
Di Nardo, Anna ;
Kabigting, Filamer D. ;
Dasanu, Constantin A. .
JOURNAL OF IMMUNOTHERAPY, 2010, 33 (06) :570-590
[5]
Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes [J].
Alexeev, Vitali ;
Yoon, Kyonggeun .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 (05) :1102-1110
[6]
A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis [J].
Alonso, Soledad R. ;
Tracey, Lorraine ;
Ortiz, Pablo ;
Perez-Gomez, Beatriz ;
Palacios, Jose ;
Pollan, Marina ;
Linares, Juan ;
Serrano, Salvio ;
Saez-Castillo, Ana I. ;
Sanchez, Lydia ;
Pajares, Raquel ;
Sanchez-Aguilera, Abel ;
Artiga, Maria J. ;
Piris, Miguel A. ;
Rodriguez-Peralto, Jose L. .
CANCER RESEARCH, 2007, 67 (07) :3450-3460
[7]
Cutaneous toxicities of RAF inhibitors [J].
Anforth, Rachael ;
Fernandez-Penas, Pablo ;
Long, Georgina V. .
LANCET ONCOLOGY, 2013, 14 (01) :E11-E18
[8]
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition [J].
Antonescu, Cristina R. ;
Busam, Klaus J. ;
Francone, Todd D. ;
Wong, Grace C. ;
Guo, Tianhua ;
Agaram, Narasimhan P. ;
Besmer, Peter ;
Jungbluth, Achim ;
Gimbel, Mark ;
Chen, Chin-Tung ;
Veach, Darren ;
Clarkson, Bayard D. ;
Paty, Philip B. ;
Weiser, Martin R. .
INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (02) :257-264
[9]
Sox10 regulates the development of neural crest-derived melanocytes in Xenopus [J].
Aoki, Y ;
Saint-Germain, N ;
Gyda, M ;
Magner-Fink, E ;
Lee, YH ;
Credidio, C ;
Saint-Jeannet, JP .
DEVELOPMENTAL BIOLOGY, 2003, 259 (01) :19-33
[10]
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study [J].
Ascierto, Paolo A. ;
Schadendorf, Dirk ;
Berking, Carola ;
Agarwala, Sanjiv S. ;
van Herpen, Carla M. L. ;
Queirolo, Paola ;
Blank, Christian U. ;
Hauschild, Axel ;
Beck, J. Thaddeus ;
St-Pierre, Annie ;
Niazi, Faiz ;
Wandel, Simon ;
Peters, Malte ;
Zubel, Angela ;
Dummer, Reinhard .
LANCET ONCOLOGY, 2013, 14 (03) :249-256